Edwards Lifesciences (EW) Raw Materials (2010 - 2026)

Edwards Lifesciences' Raw Materials history runs 13 years deep, the most recent figure standing at $202.4 million for Q1 2026.

• On a quarterly basis, Raw Materials fell 21.91% year-over-year to $202.4 million in Q1 2026; TTM through Mar 2026 was $202.4 million, a 21.91% decrease from a year earlier, with the FY2025 full-year figure at $196.6 million, down 18.46% from the prior year.
• Raw Materials advanced to $202.4 million in Q1 2026 per EW's latest filing, from $196.6 million in the prior quarter.
• Across five years, Raw Materials topped out at $280.0 million in Q1 2024 and bottomed at $196.3 million in Q4 2023.
• The 4-year median for Raw Materials is $237.3 million (2024), against an average of $233.0 million.
• Across the five-year window, Raw Materials grew 22.82% in 2024 and fell 21.91% in 2026, its largest moves.
• Year by year, Raw Materials stood at $196.3 million in 2023, then advanced by 22.82% to $241.1 million in 2024, then dropped by 18.46% to $196.6 million in 2025, then increased by 2.95% to $202.4 million in 2026.
• Per Business Quant, the three latest EW Raw Materials figures stand at $202.4 million (Q1 2026), $196.6 million (Q4 2025), and $222.8 million (Q3 2025).